MSTN and sarcopenia: These data suggest that myotubes differentiated from 1 μM SYUIQ-5 treated myoblasts are characterized by features typical of sarcopenic myotubes and release increased levels of MYOSTATIN that could affect skeletal muscle cell growth, thus contributing to sarcopenia.